IL22 and psoriasis: Notably, the characteristic enrichment of IL-17, IL-22 and IL-36 in PN (versus AD) may underlie its clinical overlap with psoriasis (31, 32), a mechanism validated in our PN-like model through GSVA demonstrating robust Th17/Th22 responses and IL-36 pathway activation in lesional skin.